IAA
CRSP icon

Independent Advisor Alliance’s CRISPR Therapeutics CRSP Stock Holding History

Independent Advisor Alliance’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$376K Buy
7,907
+585
+8% +$30.9K ﹤0.01% 1229
2025
Q4 		$384K Sell
7,322
-118
-2% -$7.07K 0.01% 724
2025
Q3 		$482K Sell
7,440
-267
-3% -$15.3K 0.01% 631
2025
Q2 		$375K Sell
7,707
-241
-3% -$9.33K 0.01% 668
2025
Q1 		$270K Buy
7,948
+167
+2% +$7.08K 0.01% 685
2024
Q4 		$306K Buy
7,781
+62
+0.8% +$2.93K ﹤0.01% 1133
2024
Q3 		$363K Buy
7,719
+1,745
+29% +$88.5K 0.01% 524
2024
Q2 		$323K Buy
5,974
+80
+1% +$4.63K 0.01% 555
2024
Q1 		$402K Buy
5,894
+532
+10% +$38.1K 0.01% 500
2023
Q4 		$336K Sell
5,362
-9,894
-65% -$547K 0.01% 523
2023
Q3 		$692K Buy
15,256
+11,685
+327% +$603K 0.03% 353
2023
Q2 		$200K Buy
+3,571
New +$203K 0.01% 625
2022
Q2 		– Sell
-3,842
Closed -$241K – 641
2022
Q1 		$241K Buy
3,842
+1,011
+36% +$63.5K 0.01% 555
2021
Q4 		$215K Buy
+2,831
New +$247K 0.01% 614

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Independent Advisor Alliance's CRSP Position: Q1 2026 in Review

Independent Advisor Alliance increased its CRISPR Therapeutics (CRSP) stake by 8% in Q1 2026, buying an estimated $30.9K and bringing the position to 7,907 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #1229.

Independent Advisor Alliance first reported a position in CRSP in Q4 2021 and has held it in 14 quarters since. The position peaked at $692K in Q3 2023. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Independent Advisor Alliance held 7,907 shares of CRISPR Therapeutics worth $376K as of Q1 2026.
  • Independent Advisor Alliance bought 585 CRISPR Therapeutics shares in Q1 2026, an estimated $30.9K.
  • CRISPR Therapeutics made up ﹤0.01% of Independent Advisor Alliance's portfolio in Q1 2026, its #1229 holding.
  • Independent Advisor Alliance first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Independent Advisor Alliance's CRISPR Therapeutics position peaked at $692K in Q3 2023.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Independent Advisor Alliance's 13F filing for Q1 2026, filed 12 May 2026.